Filing identity and reporting period
The supplied filing is ESGEN Acquisition Corporation’s Form 10-K for the fiscal year ended December 31, 2021, covering April 19, 2021 (inception) through year-end. It is not a Zeo Energy Corp. filing; the company and filing period in the request metadata do not match the source.
Business context
ESGEN was a newly formed SPAC with no operating business or revenue. It had not selected a business-combination target or begun substantive discussions with one by December 31, 2021. It described a primary interest in North American energy and infrastructure, particularly decarbonization, while retaining the ability to pursue other sectors and geographies.
Financial results, cash flow and liquidity
- Revenue and operations: No operating revenue. Operating costs were $776,033, producing an operating loss of $776,033.
- Net result: Net income was $9,460,263, driven principally by a $10,944,240 gain from changes in the fair value of warrant liabilities. The filing reports basic and diluted EPS of $1.96 for Class A shares and a $0.80 loss per Class B share; it also identifies a material weakness in EPS allocation controls.
- Cash flow: Net cash used in operating activities was $938,295. The company placed $281,520,000 in its trust account; cash outside the trust was $1,323,903 at year-end.
- Liquidity: Working capital was $1,267,382. Management said available resources and borrowing capacity should meet needs through the earlier of a business combination or one year from filing, but the financial statements and auditor’s report state that cash outside the trust was not expected to support 12 months of operations absent a business combination. The auditor reported substantial doubt about the company’s ability to continue as a going concern.
- Debt and liabilities: Total liabilities were $24,243,115, including $13,976,160 of warrant liabilities, $9,660,000 of deferred underwriting fees payable upon a business combination, and a $171,346 sponsor promissory note. No working-capital loans were outstanding.
- Trust and capital: The trust held marketable securities of $281,522,137 at year-end. The 27.6 million public shares were classified as temporary equity at a redemption value of $10.20 per share. The SPAC raised $276 million in its IPO and received $14.04 million from private-placement warrants; transaction costs were $16.14 million.
Changes, outlook and material risks
This is the company’s first reporting period, so the filing provides no prior comparable operating period. ESGEN had no operating revenue or business activity to compare; its reported profit primarily reflects a noncash warrant revaluation rather than operating performance.
The company had 15 months from the October 22, 2021 IPO closing to complete a business combination, with up to two three-month extensions subject to $2.76 million deposits per extension. Failure to complete a transaction would lead to liquidation and redemption of public shares; warrants would expire worthless. Management’s stated plan to address going-concern uncertainty depended on completing a business combination, with no assurance of success. No financial guidance was provided.
- Controls: Disclosure controls were deemed ineffective due to a material weakness involving insufficient qualified accounting resources and incorrect EPS allocations. Management described remediation plans but gave no assurance they would be effective.
- Conflicts and dilution: Sponsor and management interests may differ from public shareholders; founder shares were acquired at approximately $0.004 each and convert at a target ownership formula. Additional equity, debt, redemptions and warrant exercises may affect ownership and transaction terms.
- Other risks: The filing highlights target scarcity and SPAC competition, redemption-related funding uncertainty, potential claims against trust funds, COVID-19 and market disruption, and dependence on sponsor financing that is not committed. It reports no material litigation pending.
Investor facts to verify
- Confirm the issuer: the source is ESGEN Acquisition Corporation, not Zeo Energy Corp.
- Review the audited statements and EPS disclosures in light of the reported material weakness and the filing’s stated EPS-allocation error.
- Assess cash available outside the trust, sponsor-note repayment terms, and the conflicting liquidity and going-concern statements.
- Verify the trust balance, redemption terms, extension funding requirements and business-combination deadline.
- Evaluate warrant-liability valuation and potential founder-share, financing and warrant dilution before treating reported net income as indicative of operating performance.